Financial Data and Key Metrics Changes - The meeting confirmed the reelection of four directors and the ratification of Deloitte and Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025 [21][22]. Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed during the meeting [11]. Market Data and Key Metrics Changes - No specific market data or key metrics were provided during the meeting [11]. Company Strategy and Development Direction and Industry Competition - The company continues to focus on maintaining strong governance with the reelection of its board members and the appointment of its auditors, indicating a commitment to transparency and accountability [20][21]. Management's Comments on Operating Environment and Future Outlook - Management expressed appreciation for shareholder support but did not provide specific comments on the operating environment or future outlook during the meeting [25]. Other Important Information - The meeting was conducted virtually, and all necessary logistics were followed to ensure proper governance and shareholder participation [5][6][19]. Q&A Session Summary - There were no questions submitted during the Q&A session, and the meeting concluded without any additional inquiries [24].

Financial Data and Key Metrics Changes - In Q4, the company reported revenue of $170 million, a 26% sequential increase and up 180% year over year [4][22] - For fiscal year 2025, total revenue reached $437 million, representing a growth of 126% year over year [5][21] - Non-GAAP gross margin for Q4 was 67.4%, and for fiscal year 2025, it was 65% [5][21] - Non-GAAP operating income in Q4 was $62.5 million, compared to $42.4 million in Q3, reflecting significant leverage from revenue growth [24] Business Line Data and Key Metrics Changes - The Active Electrical Cable (AEC) product line maintained a steep growth trajectory, with significant contributions from three hyperscalers, each contributing over 10% of revenue [9][22] - The optical business achieved strong momentum, with revenue growth targets met and significant wins in 50 gig and 100 gig per lane optical DSPs [12][15] - The retimer business also delivered robust results, driven by 50 gig and 100 gig per lane Ethernet solutions [15] Market Data and Key Metrics Changes - The company noted increasing customer diversification across copper and optical connectivity for various applications, particularly in AI networks [8][20] - The demand for high-speed connectivity solutions is growing among hyperscaler customers, driven by the need for advanced AI services [20] Company Strategy and Development Direction - The company is focused on customer-driven innovation and has positioned itself as a leader in high-speed connectivity solutions, particularly in the AI landscape [6][18] - The strategy includes expanding the AEC market and enhancing optical connectivity solutions, with a commitment to energy efficiency and reliability [14][19] - The company anticipates significant growth opportunities in the optical market, particularly with the introduction of new products [14][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained revenue growth, driven by increasing customer diversification and the anticipated ramp-up of new hyperscale customers [9][33] - The company expects revenue for Q1 of fiscal 2026 to be between $185 million and $195 million, indicating a 12% sequential growth at the midpoint [26] - For fiscal year 2026, the company projects revenue to exceed $800 million, with year-over-year growth exceeding 85% [27] Other Important Information - The company ended Q4 with cash and equivalents of $431.3 million, an increase of $52.1 million from Q3 [25] - Capital expenditures (CapEx) are expected to double in fiscal year 2026 to support growth initiatives [78] Q&A Session Summary Question: Can you quantify the contribution of the largest customers? - The largest customer accounted for 61% of revenue, with two others contributing 12% and 11% respectively [32] Question: What are the expectations for gross margin in the upcoming quarters? - Gross margin is expected to trend around 65% for Q1, with potential for further expansion as scale increases [34][36] Question: Can you elaborate on the use cases for large customers? - The primary use cases include connecting servers with switches, focusing on both front-end and back-end networks [42] Question: What is the competitive landscape for AEC products? - The competitive environment has not changed significantly, and the company aims to maintain its leadership by delivering innovative solutions quickly [84][86]

Financial Data and Key Metrics Changes - The company reported a confirmed overall response rate (ORR) of 68% and a disease control rate of 93% across all dose levels in the ongoing clinical trial for ZL1310 [12][21] - The median follow-up for the efficacy evaluable patients was 3.4 months, with some patients remaining in response for over 9 months [22][43] Business Line Data and Key Metrics Changes - ZL1310, the investigational DLL3 targeted antibody-drug conjugate, demonstrated promising clinical activity in patients with relapsed or refractory extensive stage small cell lung cancer [6][19] - The safety profile of ZL1310 was reported as manageable, with only 16% of patients in the low-dose group requiring dose interruptions [10][19] Market Data and Key Metrics Changes - Small cell lung cancer accounts for approximately 15% of all lung cancers, affecting around 372,000 patients worldwide, with a poor prognosis and a median overall survival of about 13 months [6][19] - The estimated global prevalence of DLL3 expressing neuroendocrine carcinomas is roughly 350,000 to 400,000 patients, indicating a significant market opportunity for ZL1310 [26] Company Strategy and Development Direction - The company plans to initiate a registrational study in second-line small cell lung cancer later this year, with overall survival as the primary endpoint [22][23] - There is a strategy to expand ZL1310 into first-line small cell lung cancer and other DLL3 expressing solid tumors, aiming to reduce treatment burden for patients [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for accelerated approval based on the promising data and ongoing discussions with the FDA [56][57] - The company is optimistic about the efficacy of ZL1310 in the competitive landscape, particularly in comparison to existing therapies [48][49] Other Important Information - The company is exploring combination therapies with ZL1310, including carboplatin and atezolizumab, to enhance treatment efficacy [38][39] - The company has received fast track designation from the FDA, which may facilitate the development process [32] Q&A Session Summary Question: Can you comment on the therapeutic window and confidence in the selected dose for pivotal studies? - Management indicated that the 1.6 mg/kg dose shows a good balance of efficacy and safety, with a slight attrition in response at higher doses [29][30] Question: What is the dosing strategy and safety consideration for the combination trial? - The company is methodically exploring combinations with existing chemotherapy regimens and is confident in the competitive activity of ZL1310 [37][38] Question: How does the durability of ZL1310 compare to competitors in refractory small cell lung cancer? - Management noted that the durability of response is clinically meaningful, with a median follow-up of 6.9 months for the most mature data set [42][43] Question: What gives confidence in potential accelerated approval for ZL1310? - Ongoing discussions with the FDA suggest that accelerated approval is a viable option, contingent on the results of the randomized trial [56][57] Question: What are the remaining items to align with the FDA before initiating the pivotal study? - The main focus is to finalize the dosing strategy and ensure alignment on study design with the FDA [65][66]

Financial Data and Key Metrics Changes - The preliminary results indicated that the proposal to approve the 2024 compensation of named executive officers was approved, reflecting shareholder support for executive pay practices [13] - The amendment to the 2020 equity incentive plan to increase the number of shares available by 1,950,000 shares was also approved, indicating a positive outlook on employee incentives [13] - The ratification of KPMG LLP as the independent registered public accounting firm for 2025 was passed, ensuring continuity in financial oversight [13] Business Line Data and Key Metrics Changes - No specific data or metrics regarding individual business lines were discussed during the meeting [15] Market Data and Key Metrics Changes - No specific market data or metrics were provided in the meeting [15] Company Strategy and Development Direction - The company is focused on enhancing its equity incentive plan and employee stock purchase plan, which suggests a strategy aimed at retaining talent and aligning employee interests with shareholder value [13] Management Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [15] Other Important Information - The meeting was attended by key executives and board members, including the CEO and CFO, indicating strong leadership presence [3][2] - The meeting was recorded, and a webcast playback will be available for one year, ensuring transparency for shareholders [6] Q&A Session Summary Question: Were there any questions regarding the company's business? - There were no questions submitted during the Q&A session [15]

Financial Data and Key Metrics Changes - The company acknowledges that it has not fulfilled shareholder expectations and is committed to restoring performance [25][26] - The stock price has declined from $630 in 2024 to $315 currently, indicating significant market challenges [11] Business Line Data and Key Metrics Changes - The management team is focusing on improving pricing disciplines and forecasting accuracy for care and financial activity [27][28] - OptumHealth is emphasized as a critical area for evolving American healthcare from a fee-for-service model to value-based care [29][30] Market Data and Key Metrics Changes - The company is actively addressing care activity and cost trends that have led to outsized growth, indicating a need for better market alignment [27][28] Company Strategy and Development Direction - The company is undergoing a comprehensive review of operations to enhance performance and transparency [26][30] - New initiatives are being introduced to improve risk assessment, coding practices, and compliance measures [30][31] - The company aims to reinvigorate its performance culture and maintain a lean operational structure while investing in stakeholders [31][32] Management's Comments on Operating Environment and Future Outlook - Management expresses a commitment to restoring trust and confidence among shareholders and acknowledges past performance shortcomings [25][26] - A prudent earnings outlook for 2025 will be established in the upcoming second-quarter report, with initial perspectives for 2026 [31] Other Important Information - The company has received advisory approval for executive compensation and ratified the appointment of Deloitte and Touche LLP as the independent auditor for the fiscal year [22] Q&A Session Summary Question: Will you provide specific data on the factors used by AI in denying care that overrides physician/provider team assessment? - The company clarifies that AI is used to support providers and reduce administrative burdens, not to deny care [36][37] Question: Is there a retirement age for UNH directors? - The company does not have a hard policy but follows guidelines that suggest a retirement age of about 75 [38] Question: How long will it take the company to get back to normal margins on the MA business? Could this be fixed in twelve to eighteen months? - The company has suspended guidance and will not respond to financial questions until guidance is reestablished on July 29 [39] Question: Can you provide an update on your knowledge regarding government investigations? - The company will not comment on open investigations but assures that material matters will be disclosed in SEC filings [40][41]

Financial Data and Key Metrics Changes - The company reported revenue of $1,877 million for Q1 FY 2026, representing growth of approximately 2% year-over-year due to the ramp-up of new and existing programs [11] - Adjusted EBITDA for the quarter was $157 million, resulting in an adjusted EBITDA margin of 8.4% [11] - Adjusted diluted earnings per share were flat year-over-year at $1.92, impacted by a higher tax rate and lower adjusted EBITDA [12] - Free cash flow was negative $44 million, affected by the timing of receivables on two programs [12] Business Line Data and Key Metrics Changes - The company secured net bookings of $2,400 million for a book-to-bill ratio of 1.3, including key recompete contracts [10] - The backlog of pending awards remained steady at approximately $20,000 million, providing visibility into future bookings [10] - The company expects to achieve a trailing twelve-month book-to-bill ratio of 1.2 in the coming quarters [11] Market Data and Key Metrics Changes - The Department of Defense (DoD) is expected to see stronger budget support, particularly for the Navy, Air Force, and Space Force, while the Army may face challenges [6][7] - The company noted over $1 billion in additional budget for the Department of Transportation and over $40 billion for the Department of Homeland Security [9] Company Strategy and Development Direction - The company is pivoting its portfolio towards mission and enterprise IT, aligning with the new administration's strategic priorities [8] - The strategy includes leveraging proven expertise in mission integration and digital engineering to drive program success [8] - The company aims for sustained profitable growth and is focused on executing its strategy in the coming quarters [13] Management's Comments on Operating Environment and Future Outlook - The operating environment has stabilized, but there are still procurement delays and higher turnover rates among customers [5] - The company is cautiously optimistic about future growth, expecting to achieve revenue guidance of $7.6 billion to $7.75 billion for FY 2026 [15] - Management highlighted the importance of adapting to the evolving budget environment and maintaining a focus on contract growth [55][56] Other Important Information - The company repurchased approximately $125 million of shares in Q1 and targets annual repurchases of $350 million to $400 million [17][18] - The company is not seeing significant risks from recent DoD communications regarding contracting practices [75] Q&A Session Summary Question: Update on operating environment and budget priorities - Management noted that the operating environment has stabilized, with significant turnover in acquisition personnel affecting procurement processes [22] Question: Competitiveness in procurement environment - Management acknowledged increased competitiveness but expressed confidence in their submission pipeline and win rates [25][26] Question: Known headwinds from recompetes - The only significant known recompete headwind is the NASA program loss, which will conclude in Q3 [30][32] Question: Nature of cost overruns in space program - Management explained that cost overruns were due to challenges in the tech development phase, but they expect to recover as the program transitions to the sustainment phase [34][35] Question: Overview of end markets and opportunities - Management provided insights into the civilian and defense sectors, highlighting growth opportunities in various agencies and programs [44][46] Question: Impact of continuing resolutions on awards - Management indicated that while there are some delays, the solicitation of proposals remains robust, and they are optimistic about future awards [53][54] Question: Margin trajectory and expectations - Management expects civil margins to improve and defense margins to remain stable, with a focus on executing at higher bid thresholds [86]

Financial Data and Key Metrics Changes - The company reported revenue of $1,877 million for Q1 FY 2026, representing growth of approximately 2% year-over-year due to the ramp-up of new and existing programs [11] - Adjusted EBITDA for the quarter was $157 million, resulting in an adjusted EBITDA margin of 8.4% [11] - Adjusted diluted earnings per share were flat year-over-year at $1.92, impacted by a higher tax rate and lower adjusted EBITDA [12] - Free cash flow was negative $44 million, affected by the timing of receivables on two programs [12] Business Line Data and Key Metrics Changes - The company secured net bookings of $2,400 million with a book-to-bill ratio of 1.3, including key recompete contracts [10] - The backlog of pending awards remained steady at approximately $20,000 million, providing visibility into future bookings [10] - The company expects to achieve a trailing twelve-month book-to-bill ratio of 1.2 in the coming quarters [11] Market Data and Key Metrics Changes - The Department of Defense (DoD) is expected to see stronger budget support, particularly for the Navy, Air Force, and Space Force, while the Army may face challenges [6] - The company noted over $1 billion in additional budget for the Department of Transportation and over $40 billion for the Department of Homeland Security [9] - The company’s revenue from its top five civilian agency customers represents over 70% of total revenue for the civilian segment [9] Company Strategy and Development Direction - The company is pivoting its portfolio towards mission and enterprise IT, aligning with the new administration's priorities [7] - The strategy includes leveraging proven expertise in mission integration and digital engineering to drive program success [8] - The company is focused on executing its growth strategy while navigating procurement delays and changes in the operating environment [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the operating environment stabilizing, despite ongoing procurement delays and turnover among customers [5] - The company anticipates continued growth driven by new business ramping up and modest headwinds from contract transitions [14] - Management reiterated guidance for revenue growth of approximately 2.5% at the midpoint for FY 2026 [14] Other Important Information - The company repurchased approximately $125 million of shares in Q1 and continues to target annual repurchases of $350 million to $400 million [17] - The company is also exploring additional capacity for mergers and acquisitions or incremental share repurchases [17] Q&A Session Summary Question: Update on operating environment and budget priorities - Management noted that the operating environment has stabilized, with significant turnover among acquisition personnel affecting procurement processes [20][22] Question: Competitiveness in procurement environment - Management acknowledged increased competitiveness but expressed confidence in their submission pipeline and win rates [24][25] Question: Known headwinds from recompetes - The only significant known recompete headwind is the NASA program loss, which will conclude in Q3 [28][31] Question: Nature of cost overruns in fixed-price programs - Management explained that cost overruns were due to challenges in the tech development phase, but they expect to recover as the program transitions to the sustainment phase [33][34] Question: Overview of end markets and opportunities - Management provided insights into the civilian and defense markets, highlighting growth opportunities in various sectors, including command and control capabilities [41][44] Question: Impact of continuing resolutions on awards - Management indicated that while there are delays in larger awards, the overall solicitation of proposals remains robust [49][50] Question: Margin trajectory and expectations - Management expects civil margins to improve and defense margins to stabilize, with a focus on executing transitions effectively [82][88]

Financial Data and Key Metrics Changes - The third quarter earnings performance exceeded expectations, with reported net sales increasing by 4% driven by the Sovos acquisition and organic net sales growth of 1% [5][29] - Adjusted EBIT increased by 2% year-over-year, resulting in a slight margin decrease due to lower net pricing realization [9][30] - Adjusted EPS was down 3%, with a net positive contribution from the Sovos acquisition [10][30] Business Line Data and Key Metrics Changes - Meals and Beverages division reported organic net sales growth of 6%, driven by volume and mix growth of 7% [13][35] - Snacks business experienced a 5% decline in organic net sales, primarily due to lower volume and mix [20][36] - The overall consumption of Meals and Beverages leadership brands increased by 2%, while Snacks leadership brand consumption declined by 3% [11][13] Market Data and Key Metrics Changes - In-market consumption for Meals and Beverages outpaced category consumption, while Snacks lagged behind due to competitive pressures [7][10] - The consumer environment showed a preference for home-cooked meals, leading to increased demand for Meals and Beverages products [11][62] - The Snacks category faced a 3% decline in in-market consumption, attributed to deteriorating consumer confidence and increased competition [20][72] Company Strategy and Development Direction - The company is focused on near-term in-market execution and mitigating tariff impacts while investing in brand growth and capabilities [8][27] - A growth office has been established to enhance consumer insights, brand activation, and innovation [27] - The company aims to improve efficiency and effectiveness across the organization to facilitate long-term growth [27][41] Management's Comments on Operating Environment and Future Outlook - Management noted that consumers are making more deliberate spending decisions, impacting the Snacks business negatively [6][26] - The company expects adjusted earnings to be at the low end of the guidance range due to slower recovery in the Snacks business [7][39] - There is optimism regarding the sustainability of the at-home cooking trend, which has positively impacted the Meals and Beverages division [60][64] Other Important Information - The company has estimated the net incremental headwind of tariff-related costs to be up to $0.03 to $0.05 per share for fiscal 2025 [39][40] - Capital expenditures for fiscal 2025 are expected to be approximately 4.5% of net sales, reflecting a decrease from prior guidance [41] Q&A Session Summary Question: What is the pressure on the Snacks business? - Management indicated that about two-thirds of the pressure is due to overall category performance and one-third from in-market execution, with a focus on innovation and value [45][47] Question: What are the key factors for fiscal 2026? - Management noted that recovery in the Snacks business is expected to take place in fiscal 2026, with a need for increased marketing support [52][54] Question: How sustainable is the at-home cooking trend? - Management expressed optimism about the sustainability of the at-home cooking trend, supported by the company's diverse portfolio [60][64] Question: What is the impact of tariffs on future guidance? - Management clarified that the estimated tariff impact is being phased in and should not be annualized at this time due to the evolving trade landscape [75][80] Question: What is the growth expectation for Rao's? - Management expects high single-digit growth for Rao's in fiscal 2025, with confidence in the brand's trajectory [83][84]

Financial Data and Key Metrics Changes - The company reported a 4% increase in net sales, driven by the Sovos acquisition and organic net sales growth of 1% [30][31] - Adjusted EBIT increased by 2% year-over-year, with a slight margin decrease due to lower net pricing realization [9][30] - Adjusted EPS was down 3% compared to the prior year, with a net positive contribution from the Sovos acquisition [10][30] Business Line Data and Key Metrics Changes - Meals and Beverages division saw organic net sales growth of 6%, driven by volume and mix growth of 7% [13][36] - Snacks division experienced an 8% decrease in net sales, with organic net sales declining by 5% due to lower volume and mix [37][20] - The overall consumption in Meals and Beverages increased by 2%, while Snacks leadership brand consumption declined by 3% [11][12] Market Data and Key Metrics Changes - The in-market performance of the company's 16 leadership brands remained stable, with more than half holding or gaining market share [10][11] - The Meals and Beverages category outpaced overall category consumption, while Snacks lagged behind due to competitive pressures [6][10] - Consumer trends indicate a growing preference for home-cooked meals, benefiting the Meals and Beverages division [11][65] Company Strategy and Development Direction - The company is focused on near-term in-market execution and mitigating tariff impacts while investing in brand growth [7][28] - A growth office has been established to enhance capabilities in consumer insights, brand activation, and innovation [28] - The company aims to improve efficiency and effectiveness across the organization to facilitate long-term growth [28][43] Management's Comments on Operating Environment and Future Outlook - Management noted that consumer spending is becoming more intentional, impacting the Snacks business negatively [5][6] - The company expects adjusted earnings to be at the low end of the guidance range due to slower recovery in the Snacks business [6][41] - Management remains confident in the strength and long-term growth potential of the Snacks brands despite current challenges [12][27] Other Important Information - The company has estimated the net incremental headwind of tariff-related costs to be up to $0.03 to $0.05 per share for fiscal 2025 [41][42] - Capital expenditures for fiscal 2025 are expected to be approximately 4.5% of net sales, reflecting a decrease from prior guidance [43] - The company delivered approximately $110 million in total savings under its cost savings program, with 30% realized in cost of products sold [33] Q&A Session Summary Question: What is the pressure on the Snacks business? - Management indicated that about two-thirds of the pressure is due to worsening category dynamics, with one-third attributed to in-market performance [46][49] Question: What needs to happen for improvement in the Snacks category? - Management highlighted the need for improved consumer confidence and continued focus on meeting consumer needs through innovation [74][75] Question: What is the expectation for REOs growth this year? - Management expects high single-digit growth for REOs, with recent market consumption showing positive trends [88][89] Question: What is the margin outlook for the fourth quarter? - Management indicated that while Snacks margins improved sequentially in Q3, the outlook for Q4 remains cautious due to slower recovery [90]

Financial Data and Key Metrics Changes - The company reported approximately $570 million in cash, providing a runway into 2028 based on the current operating plan [7] - The overall response rate in the RESILIENT-one study was 35%, with a 40% response rate in patients who progressed after chemotherapy [17][18] - The median duration of response was just under nine months across all groups [18] Business Line Data and Key Metrics Changes - The company is advancing multiple clinical-stage programs, including CLN978 for autoimmune diseases and CLN619 for non-small cell lung cancer [6] - Zipilertinib, the oral EGFR tyrosine kinase inhibitor, has shown promising results in patients with EGFR exon 20 mutations, with breakthrough therapy designation by the FDA [11][12] Market Data and Key Metrics Changes - EGFR mutated non-small cell lung cancer accounts for 16% of all non-small cell lung cancer, with exon 20 mutations representing approximately 12%, translating to an annual incidence of about 3,000 to 5,000 patients in the U.S. [67] - The company noted that patients with exon 20 mutations tend to have a poorer prognosis, highlighting the unmet need for effective therapies [68] Company Strategy and Development Direction - The company plans to pursue regulatory interactions for a potential U.S. NDA filing in the second half of the year [22][23] - There is an expansive development program for zipilertinib across multiple patient segments, including relapsed refractory disease and frontline settings [69][70] - The company retains 50% of the rights for zipilertinib in the U.S. and has a co-development and co-commercialization arrangement with partners at Tahoe [77][78] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the clinical profile of zipilertinib, noting its favorable safety profile compared to existing therapies [75] - The company anticipates significant uptake of zipilertinib once it becomes available, particularly as an oral option for patients [60][62] Other Important Information - The RESILIENT-two study will provide data on patients with active brain metastases and those with uncommon EGFR mutations in the second half of the year [79] - The RESILIENT-three study is ongoing, comparing zipilertinib plus chemotherapy to standard care [72] Q&A Session Summary Question: What is the efficacy of zipilertinib in patients with brain metastases? - The drug has shown encouraging preliminary data in patients with brain metastases, with good disease control observed [84][86] Question: What is the breakdown of patients in real-world settings? - Most patients are heavily pretreated, often having received chemotherapy and amivantamab before seeking other options [88][90] Question: Is there any data on the role of MET amplification in exon 20? - The response to this question was not directly addressed in the provided content, indicating a need for further research [94]